Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New potent biaryl sulfate-based hepatitis C virus inhibitors.

European journal of medicinal chemistry - 5 Jan 2017

You Youngsu, Kim Hee Sun, Bae Il Hak, Lee Seung Gi, Jee Min Hyeok, Keum Gyochang, Jang Sung Key, Kim B Moon

Abstract excerpt

The discovery of a new series of potent hepatitis C virus (HCV) NS5A inhibitors containing biaryl sulfone or sulfate cores is reported. Structure-activity relationship (SAR) studies on inhibitors containing various substitution patterns of the sulfate or sulfone core structure established that m-,m'- substituted biaryl sulfate core-based inhibitors containing an amide moiety (compound 20) or an imidazole moiety...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Interactions
Share to Amides
Share to Cardiotoxicity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to ERG1 Potassium Channel

Share to Imidazoles

Share to Sulfates

Share to Sulfones

Source

Identifiers

PMID: 27657807
DOI: 10.1016/j.ejmech.2016.09.031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New potent biaryl sulfate-based hepatitis C virus inhibitors.PMID 27657807Read ↗

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.Semantic proximity Read ↗

Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.Semantic proximity Read ↗

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Semantic proximity Read ↗

Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs.Semantic proximity Read ↗

Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.Semantic proximity Read ↗

Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.Semantic proximity Read ↗

Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.Semantic proximity Read ↗

Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.Semantic proximity Read ↗

In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.Semantic proximity Read ↗

Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.